# EDGAR Filing Document

**Accession Number:** 0000704532
**File Stem:** 0001193125-25-270040
**Filing Date:** 2025-11
**Character Count:** 135889
**Document Hash:** c51949f699d9a5c8ad5e3a628f14405b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-270040.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001193125-25-270040

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 91

**CONFORMED PERIOD OF REPORT**: 20250927

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ONTO INNOVATION INC.
- **CENTRAL INDEX KEY:** 0000704532
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEASURING & CONTROLLING DEVICES, NEC [3829]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 942276314
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1226

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39110
- **FILM NUMBER:** 251459404

**BUSINESS ADDRESS:**
- **STREET 1:** 16 JONSPIN ROAD
- **CITY:** WILMINGTON
- **STATE:** MA
- **ZIP:** 01887
- **BUSINESS PHONE:** 9782536200

**MAIL ADDRESS:**
- **STREET 1:** 16 JONSPIN ROAD
- **CITY:** WILMINGTON
- **STATE:** MA
- **ZIP:** 01887

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Onto Innovation Inc.
- **DATE OF NAME CHANGE:** 20191025

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NANOMETRICS INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? 10-Q

[**<u>**Table of Contents**</u>**](#toc_page)

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM** 10-Q

------

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the Quarterly Period Ended** **September 27,** 2025

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to**

**Commission File No.** 001-39110

------

ONTO INNOVATION INC.

**(Exact name of registrant as specified in its charter)**

------

Delaware 94-2276314 <br> (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification Number)

16 Jonspin Road**,** Wilmington**,** Massachusetts 01887

**(Address of principal executive offices, including zip code)**

**Registrant's telephone number, including area code: (**978**)** 253-6200

**Securities registered pursuant to Section 12(b) of the Act**

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on Which Registered** |
| Common Stock, $0.001 par value per share | ONTO | New York Stock Exchange (NYSE) |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the Registrant's Common Stock on October 15, 2025 was 49,011,162.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| Item No. |  | Page |
|  | **PART I FINANCIAL INFORMATION** |  |
| Item 1. | [Financial Statements (unaudited)](#condensed_consolidated_statements_operat) | 1 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Operations for the three and nine-months ended September 27, 2025 and September 28, 2024](#condensed_consolidated_statements_operat) | 1 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Comprehensive Income for the three and nine-months ended September 27, 2025 and September 28, 2024](#condensed_consolidated_statements_compre) | 2 |
|  | [Condensed Consolidated Balance Sheets at September 27, 2025 and December 28, 2024](#condensed_consolidated_balance_sheets) | 3 |
|  | [Condensed Consolidated Statements of Cash Flows for the nine-months ended September 27, 2025 and September 28, 2024](#condensed_consolidated_statements_cash_f) | 4 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Stockholders' Equity for the three and nine-months ended September 27, 2025 and September 28, 2024](#condensed_consolidated_stockholders_equi) | 5 |
|  | [Notes to Condensed Consolidated Financial Statements](#notes_to_condensed_consolidated_financia) | 7 |
| Item 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#item_2_managements_discussion_analysis_f) | 22 |
| Item 3. | [Quantitative and Qualitative Disclosures about Market Risk](#item_3_quantitative_qualitative_disclosu) | 29 |
| Item 4. | [Controls and Procedures](#item_4_controls_procedures) | 29 |
|  | **PART II OTHER INFORMATION** |  |
| Item 1. | [Legal Proceedings](#item_1_legal_proceedings) | 30 |
| Item 1A. | Risk Factors | 30 |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#item_2_unregistered_sales_equity_securit) | 30 |
| Item 3. | [Defaults Upon Senior Securities](#item_3_defaults_upon_senior_securities) | 30 |
| Item 4. | [Mine Safety Disclosures](#item_4_mine_safety_disclosures) | 30 |
| Item 5. | [Other Information](#item_5_or_information) | 31 |
| Item 6. | [Exhibits](#item_6__exhibits) | 31 |

---

[Signatures](#signatures)

------

[**<u>**Table of Contents**</u>**](#toc_page)

**PART I FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**ONTO INNOVATION INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(In thousands, except per share data)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue | $218193 | $252210 | $738397 | $723382 |
| Cost of revenue | 107570 | 115831 | 362419 | 340482 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 110623 | 136379 | 375978 | 382900 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 32493 | 28277 | 95815 | 81876 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 17103 | 19451 | 51729 | 56635 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 24820 | 20298 | 72608 | 57363 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 8445 | 13114 | 25336 | 39338 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and other | 4074 | 2167 | 11421 | 3046 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 86935 | 83307 | 256909 | 238258 |
| Operating income | 23688 | 53072 | 119069 | 144642 |
| Interest income, net | 9290 | 8667 | 27187 | 24524 |
| Other (expense) income, net | (999) | (724) | (2879) | 10 |
| Income before provision for income taxes | 31979 | 61015 | 143377 | 169176 |
| Provision for income taxes | 3755 | 7964 | 17147 | 16323 |
| Net income | $28224 | $53051 | $126230 | $152853 |
| Earnings per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.58 | $1.07 | $2.57 | $3.10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.57 | $1.07 | $2.57 | $3.08 |
| Weighted average number of shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 49023 | 49426 | 49044 | 49333 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 49106 | 49694 | 49178 | 49669 |

---

The accompanying notes are an integral part of these financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ONTO INNOVATION INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

**(In thousands)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net income | $28224 | $53051 | $126230 | $152853 |
| Other comprehensive income (loss), net of tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in net unrealized gains on <br>&nbsp;&nbsp;&nbsp;&nbsp; available-for-sale marketable securities | 191 | 2162 | 423 | 1304 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in currency translation adjustments | (1864) | 4859 | 7017 | 270 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss), net of tax | (1673) | 7021 | 7440 | 1574 |
| Total comprehensive income | $26551 | $60072 | $133670 | $154427 |

---

The accompanying notes are an integral part of these financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ONTO INNOVATION INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(In thousands)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **September 27,<br>2025** | **December 28,<br>2024** |
| **ASSETS** |  |  |
| *Current Assets:* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $603085 | $212945 |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 380843 | 639383 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, less allowance of $2,295 at September 27, 2025 and $2,585 at December 28, 2024 | 260197 | 308142 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 259370 | 286979 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 41441 | 30073 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1544936 | 1477522 |
| Property, plant and equipment, net | 129071 | 123868 |
| Goodwill | 330037 | 329980 |
| Identifiable intangible assets, net | 102121 | 127457 |
| Deferred income taxes | 57203 | 42811 |
| Other assets | 23242 | 15453 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $2186610 | $2117091 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| *Current liabilities:* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $52925 | $56261 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 48913 | 49974 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 30764 | 33828 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 30268 | 30026 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 162870 | 170089 |
| Deferred and other tax liabilities | 4 | 4 |
| Other non-current liabilities | 21670 | 21116 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 184544 | 191209 |
| Commitments and contingencies |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock | 49 | 49 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 1275184 | 1275146 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (6423) | (13863) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated earnings | 733256 | 664550 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 2002066 | 1925882 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $2186610 | $2117091 |

---

The accompanying notes are an integral part of these financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ONTO INNOVATION INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In thousands)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** |
|  | **2025** | **2024** |
| Cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | $126230 | $152853 |
| Adjustments to reconcile net income to net cash and cash equivalents provided by<br>operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangibles | 25336 | 39338 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of discount on marketable securities | (4292) | (5353) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 15174 | 10818 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 20378 | 21826 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for inventory valuation | 20385 | 5925 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (14509) | (15951) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | 4624 | (97) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities | 39993 | (19682) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash and cash equivalents provided by operating activities | 233319 | 189677 |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of marketable securities | (421154) | (538132) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from maturities and sales of marketable securities | 684526 | 342958 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment | (23384) | (27277) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of non-marketable equity securities | (8000) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisitions, net of cash acquired | (57) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash and cash equivalents provided by (used in) investing activities | 231931 | (222451) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases and retirement of common stock | (75015) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax payments related to shares withheld for share-based compensation plans | (12589) | (18441) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of contingent consideration for acquired business |  | (737) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares through share-based compensation plans | 9740 | 9178 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash and cash equivalents used in financing activities | (77864) | (10000) |
| Effect of exchange rate changes on cash and cash equivalents | 2754 | (1996) |
| Net increase (decrease) in cash and cash equivalents | 390140 | (44770) |
| Cash and cash equivalents at beginning of period | 212945 | 233508 |
| Cash and cash equivalents at end of period | $603085 | $188738 |
| Supplemental disclosure of cash flow information: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes paid (net of refunds) | $35468 | $30232 |

---

The accompanying notes are an integral part of these financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ONTO INNOVATION INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(In thousands)**

**(Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Additional <br>Paid-in** | **Accumulated<br>Other<br>Comprehensive** | **Accumulated** |  |
|  | **Shares** | **Amount** | **Capital** | **Loss** | **Earnings** | **Total** |
| Balance at December 28, 2024 | 49238 | $49 | $1275146 | $(13863) | $664550 | $1925882 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 64095 | 64095 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation |  |  | 6814 |  |  | 6814 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares through <br>&nbsp;&nbsp;&nbsp;&nbsp;share-based compensation <br>&nbsp;&nbsp;&nbsp;&nbsp;plans, net | 140 |  | 4179 |  |  | 4179 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of common stock | (492) |  | (17491) |  | (57524) | (75015) |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation plan <br>&nbsp;&nbsp;&nbsp;&nbsp;withholdings | (49) |  | (8684) |  |  | (8684) |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency translation |  |  |  | 2013 |  | 2013 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on investments |  |  |  | 338 |  | 338 |
| Balance at March 29, 2025 | 48837 | $49 | $1259964 | $(11512) | $671121 | $1919622 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 33911 | 33911 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation |  |  | 6678 |  |  | 6678 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares through <br>&nbsp;&nbsp;&nbsp;&nbsp;share-based compensation <br>&nbsp;&nbsp;&nbsp;&nbsp;plans, net | 137 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation plan <br>&nbsp;&nbsp;&nbsp;&nbsp;withholdings | (37) |  | (3707) |  |  | (3707) |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency translation |  |  |  | 6868 |  | 6868 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on investments |  |  |  | (106) |  | (106) |
| Balance at June 28, 2025 | 48937 | $49 | $1262935 | $(4750) | $705032 | $1963266 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 28224 | 28224 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation |  |  | 6886 |  |  | 6886 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares through <br>&nbsp;&nbsp;&nbsp;&nbsp;share-based compensation <br>&nbsp;&nbsp;&nbsp;&nbsp;plans, net | 76 |  | 5561 |  |  | 5561 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation plan <br>&nbsp;&nbsp;&nbsp;&nbsp;withholdings | (4) |  | (198) |  |  | (198) |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency translation |  |  |  | (1864) |  | (1864) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on investments |  |  |  | 191 |  | 191 |
| Balance at September 27, 2025 | 49009 | $49 | $1275184 | $(6423) | $733256 | $2002066 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Additional <br>Paid-in** | **Accumulated<br>Other<br>Comprehensive** | **Accumulated** |  |
|  | **Shares** | **Amount** | **Capital** | **Loss** | **Earnings** | **Total** |
| Balance at December 30, 2023 | 49086 | $49 | $1262029 | $(7899) | $482356 | $1736535 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 46853 | 46853 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation |  |  | 6486 |  |  | 6486 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares through <br>&nbsp;&nbsp;&nbsp;&nbsp;share-based compensation <br>&nbsp;&nbsp;&nbsp;&nbsp;plans, net | 169 |  | 4015 |  |  | 4015 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation plan <br>&nbsp;&nbsp;&nbsp;&nbsp;withholdings | (53) |  | (9088) |  |  | (9088) |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency translation |  |  |  | (2593) |  | (2593) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on investments |  |  |  | (657) |  | (657) |
| Balance at March 30, 2024 | 49202 | $49 | $1263442 | $(11149) | $529209 | $1781551 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 52949 | 52949 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation |  |  | 8244 |  |  | 8244 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares through <br>&nbsp;&nbsp;&nbsp;&nbsp;share-based compensation <br>&nbsp;&nbsp;&nbsp;&nbsp;plans, net | 181 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation plan <br>&nbsp;&nbsp;&nbsp;&nbsp;withholdings | (44) |  | (8871) |  |  | (8871) |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency translation |  |  |  | (1996) |  | (1996) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on investments |  |  |  | (201) |  | (201) |
| Balance at June 29, 2024 | 49339 | $49 | $1262815 | $(13346) | $582158 | $1831676 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 53051 | 53051 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation |  |  | 7096 |  |  | 7096 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares through <br>&nbsp;&nbsp;&nbsp;&nbsp;share-based compensation <br>&nbsp;&nbsp;&nbsp;&nbsp;plans, net | 53 |  | 5163 |  |  | 5163 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases and retirement of common stock |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation plan <br>&nbsp;&nbsp;&nbsp;&nbsp;withholdings | (2) |  | (482) |  |  | (482) |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency translation |  |  |  | 4859 |  | 4859 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on investments |  |  |  | 2162 |  | 2162 |
| Balance at September 28, 2024 | $49390 | $49 | $1274592 | $(6325) | $635209 | $1903525 |

---

The accompanying notes are an integral part of these financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ONTO INNOVATION INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**NOTE 1. Basis of Presentation**

The accompanying interim unaudited Condensed Consolidated Financial Statements have been prepared by Onto Innovation Inc. (together with its consolidated subsidiaries, unless otherwise specified or suggested by the context, the "Company," "Onto Innovation," "we," "our" or "us") and in the opinion of management reflect all adjustments, consisting of normal recurring accruals, necessary for their fair presentation in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain reclassifications have been made to prior-period amounts to conform to current-period presentation. Preparing financial statements requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ materially from reported amounts. The interim results for the three and nine-month periods ended September 27, 2025 are not necessarily indicative of results to be expected for the entire year or any future periods. This interim financial information should be read in conjunction with the financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 28, 2024 (the "2024 Form 10-K") filed with the Securities and Exchange Commission on February 25, 2025. The accompanying Condensed Consolidated Balance Sheet at December 28, 2024 has been derived from the audited consolidated financial statements included in the 2024 Form 10-K.

The Company operates on a 52- or 53-week fiscal year ending on the Saturday closest to December 31. Our fiscal year ending January 3, 2026 ("fiscal year 2025") is a 53-week fiscal year. The first quarter of the Company's fiscal year 2025 ended on March 29, 2025, the second quarter ended on June 28, 2025 and the third quarter ended on September 27, 2025. Our fiscal year ended December 28, 2024 was a 52-week fiscal year. The third quarter of the fiscal year ended December 28, 2024 ended on September 28, 2024.

**Use of Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates made by management include excess and obsolete inventory, fair value of assets acquired and liabilities assumed in a business combination, recoverability and useful lives of property, plant and equipment and identifiable intangible assets, recoverability of goodwill, recoverability of deferred tax assets, allowance for credit losses, liabilities for product warranty, share-based payments and liabilities for tax uncertainties. Actual results could differ from those estimates.

These estimates and assumptions are based on historical experience and on various other factors which the Company believes to be reasonable under the circumstances. The Company may engage third-party valuation specialists to assist with estimates related to the valuation of financial instruments, assets and stock awards associated with various contractual arrangements. Such estimates often require the selection of appropriate valuation methodologies and significant judgment. Actual results could differ from these estimates under different assumptions or circumstances and such differences could be material.

**Recent Accounting Pronouncements**

*Updates Not Yet Effective*

In September 2025, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2025-06, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which removes all references to software development stages and clarifies the threshold entities apply to begin capitalizing costs. ASU No. 2025-06 is effective for annual periods beginning after December 15, 2027 and interim reporting periods within those annual reporting periods. The ASU may be applied prospectively, retrospectively or through a modified transition approach with early adoption permitted. The Company is currently evaluating the potential impact of this standard on its consolidated financial statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

In July 2025, the FASB issued ASU No. 2025-05, Financial Instruments - Credit Losses (Topic 326), which simplifies the estimation of credit losses on current accounts receivable and current contract assets arising from transactions accounted for under Accounting Standards Codification 606, Revenue from Contracts with Customers. The guidance allows all entities to use a practical expedient to assume that the current conditions as of the balance sheet date will remain unchanged for the remaining life of the asset when developing a reasonable and supportable forecast as part of estimating expected credit losses on these assets. The guidance is effective for fiscal years beginning after December 15, 2025, and interim periods within those fiscal years. Early adoption is permitted. Entities that elect the practical expedient are required to apply the amendments prospectively. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.

Other than the standards listed above, there have been no recent accounting pronouncements or changes in accounting pronouncements during the three and nine months ended September 27, 2025, as compared to the recent accounting pronouncements described in the 2024 Form 10-K, that are of significance, or potential significance, to the Company.

**NOTE 2. Acquisitions**

*Proposed Acquisition*

On June 27, 2025, we entered into an Equity Purchase Agreement (the "Purchase Agreement") to acquire all the outstanding membership interests of Semilab USA LLC ("Semilab USA") from Semilab International Zrt. ("Semilab"), for $475.0 million in cash (subject to certain customary purchase price adjustments) and 706,215 shares of the Company's common stock (the "Transaction"). On September 25, 2025, each of the Company and Semilab received a request for additional information and documentary material (a "Second Request") from the U.S. Department of Justice in connection with the Transaction. In response to the Second Request, and in order to increase the likelihood of a timely closing for the Transaction, on October 9, 2025, the parties entered into an amendment to the Purchase Agreement (the "Purchase Agreement Amendment"), pursuant to which the parties agreed that the Fourier-Transform infrared spectroscopy reflectometry systems business conducted by Semilab and its affiliates would not be included in the Transaction and would instead be retained by Semilab. The Purchase Agreement Amendment amends the purchase price that the Company will pay to Semilab in the transaction to $432.3 million in cash (subject to certain customary purchase price adjustments) and 641,771 shares of the Company's common stock, par value $0.001 per share. This represents a reduction of approximately $50.0 million in total Transaction value to approximately $495.0 million based upon the closing value of the Company's common stock on June 27, 2025. The Company continues to anticipate that the Transaction will be completed in 2025.

For the three and nine months ended September 27, 2025, the Company incurred $2.1 million and $4.6 million of Transaction-related costs, respectively, in each case recorded within the caption "General and administrative" in the Company's Condensed Consolidated Statements of Operations.

**NOTE 3. Fair Value Measurements**

*Fair Value of Financial Instruments*

The Company has evaluated the estimated fair value of financial instruments using available market information and valuations as provided by third-party sources. The use of different market assumptions and/or estimation methodologies could have a significant effect on the estimated fair value amounts. The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximates fair value because of the short-term maturity of these instruments.

*Fair Value Hierarchy*

The Company applies a three-level valuation hierarchy for fair value measurements. This hierarchy prioritizes the inputs into three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability. Level 3 inputs are unobservable inputs based on management's assumptions used to measure assets and liabilities at fair value. A financial

------

[**<u>**Table of Contents**</u>**](#toc_page)

asset's or liability's fair value measurement classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

The following tables provide the assets and liabilities carried at fair value measured on a recurring basis at September 27, 2025 and December 28, 2024:

---

| | | |
|:---|:---|:---|
|  | **Fair Value Measurements Using<br>Significant Other Observable<br>Inputs (Level 2)** | **Fair Value Measurements Using<br>Significant Other Observable<br>Inputs (Level 2)** |
|  | **September 27,<br>2025** | **December 28,<br>2024** |
|  | **(in thousands)** | **(in thousands)** |
| Assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Available-for-sale debt securities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government notes and bonds | $197257 | $284863 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificates of deposit | 60621 | 73421 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | 50922 | 136557 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate bonds | 72043 | 144542 |
| &nbsp;&nbsp;&nbsp;&nbsp; Foreign currency forward contracts | 67 | 61 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $380910 | $639444 |

---

Available-for-sale debt securities classified as Level 2 are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. The foreign currency forward contracts are primarily measured based on the foreign currency spot and forward rates quoted by the banks or foreign currency dealers. Investment prices are obtained from third-party pricing providers, which model prices utilizing the above observable inputs, for each asset class.

See Note 4 for additional discussion regarding the fair value of the Company's marketable securities.

*Non-recurring Fair Value Measurements*

During the nine-month period ended September 27, 2025, the Company invested $8.0 million in the equity of a privately-held company. There were no such investments at December 28, 2024. This non-marketable equity investment is recorded at fair value on a non-recurring basis and is classified as a Level 3 asset in "Other assets" on the Condensed Consolidated Balance Sheets. This non-marketable equity investment is generally accounted for under the measurement alternative, defined as cost, less impairments, adjusted for subsequent observable price changes and is periodically assessed for impairment when events or circumstances indicate that decline in value may have occurred. As of September 27, 2025, there have been no impairments recorded for the non-marketable equity investment.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**NOTE 4. Marketable Securities**

At September 27, 2025 and December 28, 2024, marketable securities are categorized as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Amortized Cost** | **Gross Unrealized Holding Gains** | **Gross Unrealized Holding Losses** | **Fair Value** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| **September 27, 2025** |  |  |  |  |
| Government notes and bonds | $196607 | $669 | $19 | $197257 |
| Certificates of deposit | 60570 | 51 |  | 60621 |
| Commercial paper | 50910 | 15 | 3 | 50922 |
| Corporate bonds | 71818 | 225 |  | 72043 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | $379905 | $960 | $22 | $380843 |
| **December 28, 2024** |  |  |  |  |
| Government notes and bonds | $284763 | $387 | $287 | $284863 |
| Certificates of deposit | 73390 | 49 | 18 | 73421 |
| Commercial paper | 136496 | 103 | 42 | 136557 |
| Corporate bonds | 144331 | 283 | 72 | 144542 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | $638980 | $822 | $419 | $639383 |

---

The amortized cost and estimated fair value of marketable securities classified by the maturity date listed on the security, regardless of the Condensed Consolidated Balance Sheets classification, are as follows at September 27, 2025 and December 28, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **September 27, 2025** | **September 27, 2025** | **December 28, 2024** | **December 28, 2024** |
|  | **Amortized Cost** | **Fair Value** | **Amortized Cost** | **Fair Value** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Due within one year | $288860 | $289282 | $432088 | $432616 |
| Due after one through five years | 91045 | 91561 | 140917 | 140792 |
| Due after five through ten years |  |  | 235 | 235 |
| Due after ten years |  |  | 65740 | 65740 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | $379905 | $380843 | $638980 | $639383 |

---

The Company has evaluated its investment policies and determined that all of its marketable securities, which are comprised of debt securities, are to be classified as available-for-sale. The Company's available-for-sale debt securities are carried at fair value, with the unrealized gains and losses reported in Stockholders' equity under the caption "Accumulated other comprehensive loss." Gross realized gains and losses on available-for-sale securities are included in "Other (expense) income, net" on the Condensed Consolidated Statements of Operations and were not material during the three and nine-months ended September 27, 2025 and September 28, 2024. The Company records credit losses for its available-for-sale debt securities when it intends to sell the securities, it is more likely than not that it will be required to sell the securities before a recovery, or when it does not expect to recover the entire amortized cost basis of the securities. The cost of securities sold is based on the specific identification method.

The Company has determined that the gross unrealized losses on its marketable securities at September 27, 2025 and December 28, 2024 are temporary in nature. The Company regularly reviews its investment portfolio to identify and evaluate marketable securities that have indications of possible impairment from credit losses or other factors. Factors considered in determining whether an unrealized loss is considered to be a credit loss include the length of time and extent to which fair value has been less than the cost basis, credit quality and the Company's ability and intent to hold the securities for a period of time sufficient to allow for any anticipated recovery in market value.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The following table summarizes the estimated fair value and gross unrealized holding losses of marketable securities, aggregated by investment instrument and period of time in an unrealized loss position, at September 27, 2025 and December 28, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **In Unrealized Loss Position For<br>Less Than 12 Months** | **In Unrealized Loss Position For<br>Less Than 12 Months** | **In Unrealized Loss Position For<br>Greater Than 12 Months** | **In Unrealized Loss Position For<br>Greater Than 12 Months** |
|  | **Fair Value** | **Gross Unrealized Losses** | **Fair Value** | **Gross Unrealized Losses** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| **September 27, 2025** |  |  |  |  |
| Government notes and bonds | $11152 | $11 | $3573 | $9 |
| Certificates of deposit |  |  | 2000 |  |
| Commercial paper | 14597 | 1 | 8457 | 1 |
| Corporate bonds |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $25749 | $12 | $14030 | $10 |
| **December 28, 2024** |  |  |  |  |
| Government notes and bonds | $37636 | $287 | $— | $— |
| Certificates of deposit | 8260 | 18 |  |  |
| Commercial paper | 18317 | 42 |  |  |
| Corporate bonds | 13260 | 71 | 3200 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $77473 | $418 | $3200 | $1 |

---

See Note 3 for additional discussion regarding the fair value of the Company's marketable securities.

**NOTE 5. Derivative Instruments and Hedging Activities**

The Company, when it considers it to be appropriate, enters into forward contracts to hedge the economic exposures arising from foreign currency denominated transactions. These contracts are typically denominated in euro, Chinese renminbi, Japanese yen, Korean won, Singapore dollars, and Taiwanese dollars. Foreign currency forward contracts are not designated as hedges for accounting purposes, and therefore, the change in fair value is recorded in "Other (expense) income, net," in the Condensed Consolidated Statements of Operations. The Company records its forward contracts at fair value in either "Prepaid expenses and other current assets" or "Other current liabilities" in the Condensed Consolidated Balance Sheets.

The dollar equivalent of the U.S. dollar forward contracts and related fair values as of September 27, 2025 and December 28, 2024 were as follows:

---

| | | |
|:---|:---|:---|
|  | **September 27, 2025** | **December 28, 2024** |
|  | **(in thousands)** | **(in thousands)** |
| Notional amount | $45105 | $45883 |
| Fair value of asset | $67 | $61 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

**NOTE 6. Goodwill and Purchased Intangible Assets** 

*Goodwill*

The changes in the carrying amount of goodwill are as follows:

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** |
|  | **2025** | **2024** |
|  | **(in thousands)** | **(in thousands)** |
| Balance, beginning of the period | $329980 | $315811 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustment for previously acquired business | 57 |  |
| Balance, end of the period | $330037 | $315811 |

---

*Purchased Intangible Assets*

Purchased intangible assets as of September 27, 2025 and December 28, 2024 are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Gross Carrying Amount** | **Accumulated Amortization** | **Net** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| **September 27, 2025** |  |  |  |
| Finite-lived intangibles: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Developed technology | $277416 | $208718 | $68698 |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer and distributor relationships | 66621 | 36110 | 30511 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademarks and trade names | 14171 | 11259 | 2912 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total identifiable intangible assets | $358208 | $256087 | $102121 |
| **December 28, 2024** |  |  |  |
| Finite-lived intangibles: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Developed technology | $387716 | $298013 | $89703 |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer and distributor relationships | 73321 | 39370 | 33951 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademarks and trade names | 14171 | 10368 | 3803 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total identifiable intangible assets | $475208 | $347751 | $127457 |

---

During the nine months ended September 27, 2025, the Company disposed of fully amortized identifiable intangible assets whose gross carrying value totaled $117 million. There were no disposals of identifiable intangible assets during the three and nine months ended September 28, 2024.

Assuming no change in the gross carrying value of identifiable intangible assets and estimated lives, future estimated amortization expenses are:

---

| | |
|:---|:---|
|  | **Expected Amortization** |
|  | **Expense** |
| **Fiscal Year:** | **(in thousands)** |
| 2025 (remainder) | $8445 |
| 2026 | 32588 |
| 2027 | 24367 |
| 2028 | 13482 |
| 2029 | 6232 |
| 2030 | 6109 |
| Thereafter | 10898 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $102121 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

**NOTE 7. Balance Sheet Components**

*Inventories*

Inventories, net are comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **September 27, 2025** | **December 28, 2024** |
|  | **(in thousands)** | **(in thousands)** |
| Materials | $185709 | $176814 |
| Work-in-process | 54283 | 91672 |
| Finished goods | 19378 | 18493 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total inventories, net | $259370 | $286979 |

---

*Property, Plant and Equipment*

Property, plant and equipment, net is comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **September 27, 2025** | **December 28, 2024** |
|  | **(in thousands)** | **(in thousands)** |
| Machinery and equipment | $94716 | $86317 |
| Land and building | 47611 | 46583 |
| Computer equipment and software | 40123 | 32755 |
| Leasehold improvements | 22639 | 20405 |
| Furniture and fixtures | 3922 | 4081 |
| &nbsp;&nbsp;Total property, plant and equipment, gross | 209011 | 190141 |
| Accumulated depreciation | (79940) | (66273) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total property, plant and equipment, net | $129071 | $123868 |

---

*Other assets*

Other assets are comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **September 27, 2025** | **December 28, 2024** |
|  | **(in thousands)** | **(in thousands)** |
| Operating lease right-of-use assets | $13044 | $13939 |
| Non-marketable equity securities | 8000 |  |
| Other | 2198 | 1514 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other assets | $23242 | $15453 |

---

*Accrued liabilities*

Accrued liabilities are comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **September 27, 2025** | **December 28, 2024** |
|  | **(in thousands)** | **(in thousands)** |
| Payroll and related expenses | $37667 | $39850 |
| Warranty | 11194 | 10075 |
| Other | 52 | 49 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total accrued liabilities | $48913 | $49974 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

*Other current liabilities*

Other current liabilities are comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **September 27, 2025** | **December 28, 2024** |
|  | **(in thousands)** | **(in thousands)** |
| Customer deposits | $6501 | $10700 |
| Current operating lease obligations | 5625 | 5416 |
| Income tax payable | 4002 | 8492 |
| Accrued professional fees | 2821 | 618 |
| Other accrued taxes | 7017 | 839 |
| Other | 4302 | 3961 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other current liabilities | $30268 | $30026 |

---

*Other non-current liabilities*

Other non-current liabilities are comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **September 27, 2025** | **December 28, 2024** |
|  | **(in thousands)** | **(in thousands)** |
| Non-current operating lease obligations | $8442 | $9743 |
| Unrecognized tax benefits (including interest) | 6320 | 5489 |
| Deferred revenue | 5853 | 4009 |
| Other | 1055 | 1875 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other non-current liabilities | $21670 | $21116 |

---

**NOTE 8. Commitments and Contingencies**

*Intellectual Property Indemnification Obligations*

The Company has entered into agreements with customers that include limited intellectual property indemnification obligations that are customary in the industry. These agreements generally require the Company to compensate the other party for certain damages and costs incurred as a result of third-party intellectual property claims. The nature of the intellectual property indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to its customers. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the accompanying Condensed Consolidated Financial Statements with respect to these indemnification obligations.

*Warranty Reserves*

The Company generally provides a warranty on its products for a period of 12 to 14 months against defects in material and workmanship. The Company estimates the costs that may be incurred during the warranty period and records a liability in the amount of such costs at the time revenue is recognized. The Company's estimate is based primarily on historical experience. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. Warranty provisions are generally related to current period sales. Settlements of warranty reserves are generally associated with sales that occurred during the 12 to 14 months prior to the period-end.

------

[**<u>**Table of Contents**</u>**](#toc_page)

Changes in the Company's warranty reserves are as follows:

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** |
|  | **2025** | **2024** |
|  | **(in thousands)** | **(in thousands)** |
| Balance, beginning of the period | $10858 | $9380 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accruals | 9858 | 8756 |
| &nbsp;&nbsp;&nbsp;&nbsp;Usage | (9522) | (7998) |
| Balance, end of the period | $11194 | $10138 |

---

Warranty reserves are reported in the Condensed Consolidated Balance Sheets under the captions "Accrued liabilities" and "Other non-current liabilities."

*Legal Matters*

From time to time, the Company is subject to legal proceedings and claims in the ordinary course of business. In the opinion of management, any potential liabilities resulting from any current disputes would not have a material adverse effect on the Company's unaudited interim condensed consolidated financial statements.

*Line of Credit*

The Company has a credit agreement with a bank that provides for a variable-rate line of credit which is secured by the marketable securities the Company has with the bank. The Company is permitted to borrow up to 70% of the value of eligible securities held at the time the line of credit is accessed, up to a maximum of $100.0 million. The available line of credit as of September 27, 2025 was $100.0 million with an available interest rate of 4.8%. The credit agreement is available to the Company until such time that either party terminates the arrangement at their discretion. The Company has not utilized the line of credit as of the date of this filing.

**NOTE 9. Revenue**

The following table represents a disaggregation of revenue by timing of revenue:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Point-in-time | $199831 | $237935 | $686524 | $679517 |
| Over-time | 18362 | 14275 | 51873 | 43865 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $218193 | $252210 | $738397 | $723382 |

---

See Note 15 for additional discussion of the Company's disaggregated revenue in detail.

*Contract Assets and Contract Liabilities*

Contract assets consist of amounts we have not invoiced but have completed the related performance obligation. These amounts generally arise from variances between the contractual payment terms and the transaction price assigned to the open performance obligations (e.g., we have recognized revenue in an amount greater than the amount that is billable under the contract). The contract assets amounts are recorded in "Accounts receivable" in the Condensed Consolidated Balance Sheets. As of September 27, 2025 and December 28, 2024, the Company had contract assets of $3.4 million and $10.1 million, respectively.

The Company records contract liabilities when the customer has been billed in advance of the Company completing its performance obligations primarily with respect to liabilities related to service contracts and installation. For contracts that have a duration of one year or less, these amounts are recorded as "Deferred revenue" in the Condensed Consolidated Balance Sheets. For contracts with a duration longer than one year, deferred revenue is recorded in "Other non-current liabilities" in the Condensed Consolidated Balance Sheets. As of September 27, 2025 and December 28, 2024, the Company carried a long-term deferred

------

[**<u>**Table of Contents**</u>**](#toc_page)

revenue balance of $5.9 million and $4.0 million, respectively, within "Other non-current liabilities" in the Condensed Consolidated Balance Sheets.

Changes in deferred revenue were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Balance, beginning of the period | $43545 | $31281 | $37836 | $27225 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferral of revenue | 14190 | 15926 | 65806 | 50601 |
| &nbsp;&nbsp;&nbsp;&nbsp;Recognition of current year deferred revenue | (10937) | (13173) | (40124) | (33416) |
| &nbsp;&nbsp;&nbsp;&nbsp;Recognition of prior period deferred revenue | (10181) | (4068) | (26901) | (14444) |
| Balance, end of the period | $36617 | $29966 | $36617 | $29966 |

---

**NOTE 10. Share-Based Compensation**

The following table presents the detail of share-based compensation expense amounts included in the Company's Condensed Consolidated Statement of Operations:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of revenue | $1028 | $1184 | $3030 | $3728 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 1203 | 1118 | 3557 | 4381 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 1039 | 1499 | 3029 | 4285 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 3617 | 3294 | 10284 | 9432 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and other |  |  | 478 |  |
| Total share-based compensation expense | $6887 | $7095 | $20378 | $21826 |

---

As of September 27, 2025, there was $44.1 million of total unrecognized compensation cost related to restricted stock units granted under the Company's stock plans. That cost is expected to be recognized over a weighted average period of 2.0 years following September 27, 2025.

------

[**<u>**Table of Contents**</u>**](#toc_page)

*Equity Awards*

The Company granted the following restricted stock units ("RSUs" and each, an "RSU") and market-based performance restricted stock units ("PSUs" and each, a "PSU") during the nine months ended September 27, 2025:

---

| | | | |
|:---|:---|:---|:---|
| **Awards Granted To:** | **Number of Shares<br>(in thousands)** | **Weighted Average<br>Grant Date Fair Value<br>Per Share** | **Weighted Average<br>Grant Date Fair Value<br>Per Share** |
| Directors<br> &nbsp;&nbsp;&nbsp;&nbsp;RSU <sup>(1)</sup> | 13 | $| 94.62 |
| Various executives and employees<br> &nbsp;&nbsp;&nbsp;&nbsp;RSU <sup>(2)</sup> | 294 | $| 101.65 |
| Various executives<br> &nbsp;&nbsp;&nbsp;&nbsp;PSU <sup>(3)</sup> | 49 | $| 140.94 |
| <sup>(1)</sup> These awards cliff vest one year from the grant date on May 21, 2026. | <sup>(1)</sup> These awards cliff vest one year from the grant date on May 21, 2026. | <sup>(1)</sup> These awards cliff vest one year from the grant date on May 21, 2026. | <sup>(1)</sup> These awards cliff vest one year from the grant date on May 21, 2026. |
| <sup>(2)</sup> These awards generally vest ratably over three years, one third per year beginning on the first anniversary of the grant date. These RSUs will fully vest on various dates between December 2027 and June 2028. | <sup>(2)</sup> These awards generally vest ratably over three years, one third per year beginning on the first anniversary of the grant date. These RSUs will fully vest on various dates between December 2027 and June 2028. | <sup>(2)</sup> These awards generally vest ratably over three years, one third per year beginning on the first anniversary of the grant date. These RSUs will fully vest on various dates between December 2027 and June 2028. | <sup>(2)</sup> These awards generally vest ratably over three years, one third per year beginning on the first anniversary of the grant date. These RSUs will fully vest on various dates between December 2027 and June 2028. |
| <sup>(3)</sup> These awards include PSUs with market performance conditions that will be evaluated relative to the performance of certain peers as defined in the award agreement. The number of units that ultimately vest on March 3, 2027 and March 3, 2028 will range from 0% to 200%, depending on achievement of these performance criteria. Total grant date value of these PSUs is approximately $6.9 million and was valued using the Monte Carlo method. | <sup>(3)</sup> These awards include PSUs with market performance conditions that will be evaluated relative to the performance of certain peers as defined in the award agreement. The number of units that ultimately vest on March 3, 2027 and March 3, 2028 will range from 0% to 200%, depending on achievement of these performance criteria. Total grant date value of these PSUs is approximately $6.9 million and was valued using the Monte Carlo method. | <sup>(3)</sup> These awards include PSUs with market performance conditions that will be evaluated relative to the performance of certain peers as defined in the award agreement. The number of units that ultimately vest on March 3, 2027 and March 3, 2028 will range from 0% to 200%, depending on achievement of these performance criteria. Total grant date value of these PSUs is approximately $6.9 million and was valued using the Monte Carlo method. | <sup>(3)</sup> These awards include PSUs with market performance conditions that will be evaluated relative to the performance of certain peers as defined in the award agreement. The number of units that ultimately vest on March 3, 2027 and March 3, 2028 will range from 0% to 200%, depending on achievement of these performance criteria. Total grant date value of these PSUs is approximately $6.9 million and was valued using the Monte Carlo method. |

---

**NOTE 11. Other (Expense) Income, Net**

Other (expense) income, net, is comprised of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Foreign currency exchange losses, net | $(397) | $(704) | $(2308) | $(115) |
| Other | (602) | (20) | (571) | 125 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other (expense) income, net | $(999) | $(724) | $(2879) | $10 |

---

**NOTE 12. Income Taxes**

The following table provides details of income taxes:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Income before provision for income taxes | $31979 | $61015 | $143377 | $169176 |
| Provision for income taxes | $3755 | $7964 | $17147 | $16323 |
| Effective tax rate | 12% | 13% | 12% | 10% |

---

The income tax provision for the three and nine months ended September 27, 2025 was computed based on the Company's annual forecast of profit by jurisdiction and forecasted effective tax rate for the year. The decrease in the Company's income tax provision for the three months ended September 27, 2025 compared to the three months ended September 28, 2024 was primarily due to lower profitability before taxes. The increase in the Company's income tax provision for the nine months ended September 27, 2025 compared to the nine months ended September 28, 2024 was primarily due to fewer excess tax benefits associated with equity compensation. The Company's recorded effective tax rate for the periods presented is less than the U.S. statutory rate primarily due to projected Foreign Derived Intangible Income deductions, federal research and development tax credits, and excess tax benefits associated with equity compensation.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The Company currently has a partial valuation allowance recorded against certain foreign and state net operating loss and credit carryforwards where the unrealizability of such deferred tax assets is more likely than not. Each quarter, the Company assesses the likelihood that it will be able to recover its deferred tax assets. The Company considers available evidence, both positive and negative, including forecasted earnings, in assessing its need for a valuation allowance. As a result of the Company's analysis, it concluded that it is more likely than not that a portion of its deferred tax assets will not be realized. Therefore, the Company continues to provide a valuation allowance against certain deferred tax assets. The Company continues to monitor available evidence and may reverse some or all of its remaining valuation allowance in future periods, if appropriate. The Company has a recorded valuation allowance against a certain portion of its deferred tax assets of $12.2 million at each of September 27, 2025 and December 28, 2024.

The Organization for Economic Co-operation and Development ("OECD") has been working on a Base Erosion and Profits Shifting ("BEPS") project that would change various aspects of the existing framework under which the Company's tax obligations are determined in many of the countries in which we operate. As part of the BEPS project, the OECD issued policies aimed to modernize global tax systems, including a country-by-country 15% minimum effective tax rate ("Pillar Two") for multinational companies. Numerous countries have enacted, or are in the process of enacting, legislation to implement the Pillar Two model rules with a subset of the rules becoming effective during the current year, and the remaining rules becoming effective in later periods. In June 2025, the Group of Seven ("G7") countries (Canada, France, Germany, Italy, Japan, the U.K. and the United States) agreed to exclude U.S. Multi-National entities (MNEs) from certain aspects of Pillar Two (the "G7 Statement") in exchange for the United States not imposing retaliatory taxes through the One Big Beautiful Bill Act. We will continue to monitor the G7 Statement, which has not yet been incorporated into the OECD framework. At this point in time, the Company does not expect any material tax impact associated with Pillar Two rules in the countries where it operates. As these rules continue to evolve with new legislation and guidance, the Company will continue to monitor and account for the enactment of Pillar Two and the potential impacts such rules may have on its effective tax rate and cash flows in future years.

On July 4, 2025, the United States enacted tax reform legislation through the One Big Beautiful Bill Act. Included in this legislation are provisions that allow for the immediate expensing of domestic U.S. research and development expenses, immediate expensing of certain capital expenditures, and other changes to the U.S. taxation of profits derived from foreign operations. The impact of the Act has been accounted for in the provision for taxes for the quarter ended September 27, 2025 and the amount is determined to be immaterial. The Company continues to evaluate the impact the new legislation will have on the Consolidated Financial Statements for future years. However, as the assessment is ongoing, the Company is not able to quantify the impact at this time.

**NOTE 13. Earnings Per Share**

Basic earnings per share is calculated using the weighted average number of shares of common stock outstanding during the period. Restricted stock units and employee stock purchase grants are included in the calculation of diluted earnings per share, except when their effect would be anti-dilutive. For the three and nine months ended September 27, 2025, the weighted average number of restricted stock units excluded from the computation of diluted earnings per share were 101 thousand and 80 thousand, respectively. Anti-dilutive shares for the three and nine months ended September 28, 2024 were immaterial.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The Company's basic and diluted earnings per share amounts are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** |
| Numerator: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | $28224 | $53051 | $126230 | $152853 |
| Denominator: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic earnings per share - weighted average shares<br> outstanding | 49023 | 49426 | 49044 | 49333 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of potential dilutive securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units and employee stock <br>&nbsp;&nbsp;&nbsp;&nbsp;purchase grants - dilutive shares | 83 | 268 | 134 | 336 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings per share - weighted average shares<br> outstanding | 49106 | 49694 | 49178 | 49669 |
| Earnings per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.58 | $1.07 | $2.57 | $3.10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.57 | $1.07 | $2.57 | $3.08 |

---

**NOTE 14. Accumulated Other Comprehensive Loss**

The components of accumulated other comprehensive loss, net of tax, were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Foreign currency<br>translation<br>adjustments** | **Net unrealized gains on<br>available-for-sale marketable<br>securities** | **Accumulated other<br>comprehensive loss** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Balance at December 28, 2024 | $(14491) | $628 | $(13863) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net current period other comprehensive income (loss) | 7017 | 423 | 7440 |
| Balance at September 27, 2025 | $(7474) | $1051 | $(6423) |
|  | **Foreign currency<br>translation<br>adjustments** | **Net unrealized gains on<br>available-for-sale marketable<br>securities** | **Accumulated other<br>comprehensive loss** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Balance at December 30, 2023 | $(8664) | $765 | $(7899) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net current period other comprehensive income | 270 | 1304 | 1574 |
| Balance at September 28, 2024 | $(8394) | $2069 | $(6325) |

---

For the nine-month period ended September 27, 2025, tax effects on net income of amounts recorded in other comprehensive income was $117 thousand. For the nine-month period ended September 28, 2024, tax effects on net income of amounts recorded in other comprehensive loss was $358 thousand.

**NOTE 15. Segment Reporting and Geographic Information**

The Company is organized and operates as one operating and reportable segment; the design, development, manufacture and support of high-performance control metrology, defect inspection, lithography and data analysis systems used by microelectronics device manufacturers. This determination is based on the management approach which designates internal information regularly available to the Chief Operating Decision Maker ("CODM") for making decisions and assessing performance as the source of determination of the Company's reportable segments. The Company's CODM, the Chief Executive Officer, reviews financial information presented on a consolidated basis for the purpose of making operating decisions and assessing financial performance.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The CODM uses net income as the measure of profit or loss to allocate resources and assess performance. The CODM regularly reviews net income as reported on the Company's consolidated statements of operations. Financial forecasts and budget to actual results used by the CODM to assess performance and allocate resources, as well as those used for strategic decisions related to headcount and capital expenditures are also reviewed on a consolidated basis. The CODM considers the impact of the significant segment expenses in the table below on net income when deciding whether to reinvest profits, propose share repurchase, or pursue strategic mergers and acquisitions.

The measure of segment assets is reported on the balance sheet as total assets. The CODM does not review segment assets at a level other than that presented in the Company's consolidated balance sheets.

The table below presents the Company's consolidated operating results including significant segment expenses:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Revenue | $218193 | $252210 | $738397 | $723382 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted cost of revenue <sup>(1)</sup> | 100267 | 114712 | 335289 | 337802 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted research and development <sup>(2)</sup> | 32492 | 28199 | 96505 | 81639 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted sales and marketing <sup>(2)</sup> | 17103 | 19411 | 51729 | 56515 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted general and administrative <sup>(3)</sup> | 22274 | 19889 | 66707 | 55598 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other segment items: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and other <sup>(4)</sup> | 11377 | 3251 | 38550 | 5621 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Merger and acquisitions related <sup>(4)</sup> | 2547 | 562 | 5212 | 2200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation <sup>(4)</sup> |  |  |  | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization | 8445 | 13114 | 25336 | 39338 |
| Operating income | 23688 | 53072 | 119069 | 144642 |
| Interest income, net | 9290 | 8667 | 27187 | 24524 |
| Other (expense) income, net | (999) | (724) | (2879) | 10 |
| Provision for income taxes | 3755 | 7964 | 17147 | 16323 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income | $28224 | $53051 | $126230 | $152853 |
| <sup>(1)</sup> Excludes restructuring and other expenses and merger and acquisition related expenses | <sup>(1)</sup> Excludes restructuring and other expenses and merger and acquisition related expenses | <sup>(1)</sup> Excludes restructuring and other expenses and merger and acquisition related expenses | <sup>(1)</sup> Excludes restructuring and other expenses and merger and acquisition related expenses | <sup>(1)</sup> Excludes restructuring and other expenses and merger and acquisition related expenses |
| <sup>(2)</sup> Excludes merger and acquisition related expenses | <sup>(2)</sup> Excludes merger and acquisition related expenses | <sup>(2)</sup> Excludes merger and acquisition related expenses | <sup>(2)</sup> Excludes merger and acquisition related expenses | <sup>(2)</sup> Excludes merger and acquisition related expenses |
| <sup>(3)</sup> Excludes litigation expenses and merger and acquisition related expenses | <sup>(3)</sup> Excludes litigation expenses and merger and acquisition related expenses | <sup>(3)</sup> Excludes litigation expenses and merger and acquisition related expenses | <sup>(3)</sup> Excludes litigation expenses and merger and acquisition related expenses | <sup>(3)</sup> Excludes litigation expenses and merger and acquisition related expenses |
| <sup>(4)</sup> The Company excludes these expenses in order to provide better comparability between periods as they are not representative of the Company's ongoing operations. | <sup>(4)</sup> The Company excludes these expenses in order to provide better comparability between periods as they are not representative of the Company's ongoing operations. | <sup>(4)</sup> The Company excludes these expenses in order to provide better comparability between periods as they are not representative of the Company's ongoing operations. | <sup>(4)</sup> The Company excludes these expenses in order to provide better comparability between periods as they are not representative of the Company's ongoing operations. | <sup>(4)</sup> The Company excludes these expenses in order to provide better comparability between periods as they are not representative of the Company's ongoing operations. |

---

Depreciation expense is a significant expense related to research and development expenses, sales and marketing expenses and general and administrative expenses as shown above. For the three and nine months ended September 27, 2025, depreciation expense was $5.0 million and $15.2 million, respectively. For the three and nine months ended September 28, 2024, depreciation expense was $3.9 million and $10.8 million, respectively.

The following table lists the different sources of revenue:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 27,** | **September 28,** | **September 28,** | **September 27,** | **September 27,** | **September 28,** | **September 28,** |
|  | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
|  | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** |
| Systems and software | $173795 | 80% | $217135 | 86% | $619451 | 84% | $622400 | 86% |
| Parts | 23930 | 11% | 19995 | 8% | 61955 | 8% | 56890 | 8% |
| Services | 20468 | 9% | 15080 | 6% | 56991 | 8% | 44092 | 6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $218193 | 100% | $252210 | 100% | $738397 | 100% | $723382 | 100% |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

The Company's significant operations outside the United States include sales, service and application offices in Asia and Europe. For geographical revenue reporting, revenue is attributed to the geographic location to which the product is shipped. Revenue by geographic region is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Revenue from third parties: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Taiwan | $59243 | $78273 | $227441 | $209006 |
| &nbsp;&nbsp;&nbsp;&nbsp;South Korea | 44864 | 77014 | 220828 | 227958 |
| &nbsp;&nbsp;&nbsp;&nbsp;United States | 37793 | 21979 | 90946 | 61763 |
| &nbsp;&nbsp;&nbsp;&nbsp;Japan | 16015 | 12559 | 58152 | 45172 |
| &nbsp;&nbsp;&nbsp;&nbsp;China | 27359 | 32112 | 56872 | 86222 |
| &nbsp;&nbsp;&nbsp;&nbsp;Southeast Asia | 22329 | 15589 | 44179 | 55796 |
| &nbsp;&nbsp;&nbsp;&nbsp;Europe | 10590 | 14684 | 39979 | 37465 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $218193 | $252210 | $738397 | $723382 |

---

The following customers accounted for 10% or more of total revenue for the indicated periods:

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** |
|  | **2025** | **2024** |
| Customer A | 21% | 19% |
| Customer B | 18% | 20% |
| Customer C | 14% | 13% |

---

Three customers' net accounts receivable balances were individually greater than 10% of net accounts receivable at September 27, 2025, representing, in the aggregate approximately 46% of the Company's total net accounts receivable.

Two customers' net accounts receivable balances were individually greater than 10% of net accounts receivable at December 28, 2024, representing, in the aggregate, approximately 47% of the Company's total net accounts receivable.

Substantially all of the Company's long-lived assets are located within the United States of America.

**NOTE 16. Share Repurchase Authorization**

In February 2024, the Onto Innovation Board of Directors approved a new share repurchase authorization, which allows the Company to repurchase up to $200 million worth of shares of its common stock. Repurchases may be made through both public market and private transactions from time to time. Any amount paid to repurchase the shares in excess of par value, including transaction costs, would be recorded directly as a decrease to additional paid-in capital and accumulated earnings. During the three and nine months ended September 27, 2025, 0 and 492 thousand shares of the Company's common stock were repurchased under the share repurchase authorization, respectively. At September 27, 2025, there was $99.9 million available for future share repurchases under this share repurchase authorization.

**NOTE 17. Restructuring and Other**

From time to time, the Company approves restructuring plans, which include workforce reductions, to streamline operations and align the Company's cost structure with its business outlook. These restructuring plans may result in charges to cost of goods sold for streamlining of certain manufacturing activities and other charges, including inventory write-downs primarily related to the exit of older product lines. Charges to operating expenses primarily include employee severance costs

------

[**<u>**Table of Contents**</u>**](#toc_page)

that are paid during the period incurred, charges for streamlining of certain operating activities and impairment charges such as plant, property and equipment.

Restructuring and other expenses recorded in the Condensed Consolidated Statements of Operations are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | $7303 | $1084 | $27129 | $2575 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating expenses | 4074 | 2167 | 11421 | 3046 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total restructuring and other | $11377 | $3251 | $38550 | $5621 |

---

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations** 

**Forward-Looking Statements**

Certain statements in this Form 10-Q, or incorporated by reference in this Form 10-Q, of Onto Innovation Inc. (referred to in this Form 10-Q, together with its consolidated subsidiaries, unless otherwise specified or suggested by the context, as the "Company," "Onto Innovation," "we," "our" or "us") are considered "forward-looking statements" or are based on "forward-looking statements," including, but not limited to, those concerning:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our business momentum and future growth;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•technology development, product introduction and acceptance of our products and services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our manufacturing practices and ability to deliver both products and services consistent with our customers' demands and expectations and to strengthen our market position, including our ability to source components, materials, and equipment due to supply chain delays or shortages;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the proposed acquisition of Semilab USA LLC ("Semilab USA");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations of the semiconductor market outlook;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•future revenue, gross profits, research and development and engineering expenses, selling, general and administrative expenses, and cash requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the anticipated effects of tariffs and trade disputes on our business and financial results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the effects of natural disasters or public health emergencies on the global economy and on our customers, suppliers, employees, and business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our dependence on certain significant customers and anticipated trends and developments in and management plans for our business and the markets in which we operate; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to be successful in managing our cost structure and cash expenditures and results of litigation.

Statements contained or incorporated by reference in this Form 10-Q that are not purely historical are forward-looking statements and are subject to safe harbors under Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as, but not limited to, "anticipate," "believe," "continue," "estimate," "expect," "intend," "plan," "should," "may," "could," "will," "would," "forecast," "project" and words or phrases of similar meaning, as they relate to our management or us.

Forward-looking statements contained herein reflect our current expectations, assumptions and projections with respect to future events and are subject to certain risks, uncertainties and assumptions. Actual results may differ materially and adversely from those included in such forward-looking statements as a result of various factors, including risks and uncertainties, many of which are beyond Onto Innovation's control. Such factors include, but are not limited to, the Company's ability to leverage its resources to improve its position in its core markets; its ability to weather difficult economic environments; its ability to open new market opportunities and target high-margin markets; the strength/weakness of the back-end and/or front-end semiconductor

------

[**<u>**Table of Contents**</u>**](#toc_page)

market segments; fluctuations in customer capital spending; the Company's ability to effectively manage its supply chain and adequately source components from suppliers to meet customer demand; the effects of political, economic, legal, and regulatory changes or uncertainties, changes in U.S. tariff and trade policy and related retaliatory actions, the U.S. government shutdown] and geopolitical conflicts on the Company's global operations; the Company's ability to adequately protect its intellectual property rights and maintain data security; the effects of natural disasters or public health emergencies on the global economy and on the Company's customers, suppliers, employees, and business; its ability to effectively maneuver global trade issues and changes in trade and export regulations, tariffs and license policies; the Company's ability to maintain relationships with its customers and manage appropriate levels of inventory to meet customer demands; failure to consummate or a delay in consummating the acquisition of Semilab USA, including as a result of any failure to obtain the necessary regulatory approvals or to satisfy any of the other conditions to the proposed transaction on a timely basis or at all; and the Company's ability to successfully integrate acquired businesses and technologies, including the business of Semilab USA and to realize the anticipated benefits of such acquisitions. Additional information and considerations regarding the risks faced by Onto Innovation are available in our Annual Report on Form 10-K for the fiscal year ended December 28, 2024 (the "2024 Form 10-K") filed with the Securities and Exchange Commission (the "SEC") on February 25, 2025, in Part II, Item 1A. "Risk Factors" and elsewhere in this Form 10-Q, and in the other filings that we make with the SEC from time to time. Forward-looking statements reflect our position as of the date of this Form 10-Q and we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

**Critical Accounting Estimates**

The preparation of condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States ("U.S. GAAP") requires management to make judgments, assumptions and estimates that affect the amounts reported.

Estimates and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes. In addition, management is periodically faced with uncertainties, the outcomes of which are not within our control and will not be known for prolonged periods of time. Certain of these uncertainties are discussed in the 2024 Form 10-K in the Items entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." There have been no material changes in our critical accounting estimates from the information presented in Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the 2024 Form 10-K.

For more information, please see our critical accounting estimates as previously disclosed in the 2024 Form 10-K and recent accounting pronouncements discussed in Note 1 to the Condensed Consolidated Financial Statements.

**Executive Summary**

We are a worldwide leader in the design, development, manufacture and support of metrology and inspection tools for the semiconductor industry, including process control tools that perform optical metrology on patterned and unpatterned wafers, wafer macro-defect inspection, including macro-inspection of both 2D and 3D wafer features, wafer substrate and panel substrate lithography systems, and process control analytical software. Our products are primarily used by silicon wafer manufacturers, semiconductor integrated circuit fabricators, and advanced packaging manufacturers operating in the semiconductor market. Our products are also used for process control in a number of other specialty device manufacturing markets, including light emitting diodes ("LED"), vertical-cavity surface-emitting lasers ("VCSEL"), micro-electromechanical systems ("MEMS"), CMOS image sensors ("CIS"), silicon and compound semiconductor (SiC and GaN) power devices, analog devices, RF filters, data storage, and certain industrial and scientific applications.

We provide process and yield management solutions used in bare silicon wafer production and wafer processing facilities, often referred to as "front-end" manufacturing, and advanced packaging of chips and test facilities, or "back-end" manufacturing, through a portfolio of standalone systems for optical metrology, macro-defect inspection, packaging lithography, as well as transparent and opaque thin film measurements. Our automated and integrated metrology systems measure critical dimensions, device structures, topography, shape, and various thin film compositions, including three-dimensional features and film thickness, as well as optical and material properties. Our primary areas of focus include products that provide critical yield-enhancing and actionable information, which is used by microelectronic device manufacturers to improve yield and time to market of their next-generation devices. Our systems feature sophisticated software and production-worthy automation. In addition, our advanced process control software portfolio includes powerful solutions for standalone tools, groups of tools, and factory-wide and

------

[**<u>**Table of Contents**</u>**](#toc_page)

enterprise-wide suites to enhance productivity and achieve significant cost savings. Our systems are backed by worldwide customer service and applications support.

The semiconductor and electronics industries have been characterized by constant technological innovations. We believe that, over the long term, our customers will continue to invest in advanced technologies and new materials to enable smaller design rules and higher density applications that fuel demand for process control equipment.

The following table summarizes certain key financial information for the periods indicated below:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **September 27,<br>2025** | **June 28,<br>2025** |
|  | **(in thousands, except for percentages and per share data)** | **(in thousands, except for percentages and per share data)** |
| Revenue | $218193 | $253597 |
| Gross profit | $110623 | $122122 |
| Gross profit as a percent of revenue | 51% | 48% |
| Total operating expenses | $86935 | $89875 |
| Net income | $28224 | $33911 |
| Diluted earnings per share | $0.57 | $0.69 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•In the fiscal quarter ended September 27, 2025 (the "September 2025 quarter"), revenue decreased 14% compared to the fiscal quarter ended June 28, 2025 (the "June 2025 quarter"), primarily due to lower sales to DRAM and NAND customers in the advanced node market as well as lower sales to DRAM and foundry customers in the specialty devices and advanced packaging markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Gross profit as a percentage of revenue for the September 2025 quarter increased by 3% compared to the June 2025 quarter primarily due to the write down of excess and obsolete inventory recorded in the June 2025 quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Operating expenses for the September 2025 quarter decreased by 3% compared to the June 2025 quarter primarily due to decreased restructuring expenses, research and development project costs, and compensation cost in the September 2025 quarter.

Our cash, cash equivalents and marketable securities balance increased to $983.9 million at September 27, 2025, compared to $852.3 million at December 28, 2024. This increase was primarily the result of $233.3 million of cash generated from operating activities and $9.7 million of cash from issuance of shares through share-based compensation plans, partially offset by cash used for purchases of our common stock of $75.0 million, capital expenditures of $23.4 million, $12.6 million for tax payments related to net share settlement of employee stock-based compensation plans and purchases of non-marketable equity securities of $8.0 million. Employee headcount at September 27, 2025 was approximately 1,593.

On June 27, 2025, we entered into an Equity Purchase Agreement (the "Purchase Agreement") to acquire all the outstanding membership interests of Semilab USA from Semilab International Zrt. ("Semilab"), for $475.0 million in cash (subject to certain customary purchase price adjustments) and 706,215 shares of our common stock (the "Transaction"). On September 25, 2025, each of the Company and Semilab received a request for additional information and documentary material (a "Second Request") from the U.S. Department of Justice in connection with the Transaction. In response to the Second Request, and in order to increase the likelihood of a timely closing for the Transaction, on October 9, 2025, the parties entered into an amendment to the Purchase Agreement (the "Purchase Agreement Amendment"), pursuant to which the parties agreed that the Fourier-Transform infrared spectroscopy reflectometry systems business conducted by Semilab and its affiliates would not be included in the transaction and would instead be retained by Semilab. The Purchase Agreement Amendment amends the purchase price that the Company will pay to Semilab in the Transaction to $432.3 million in cash (subject to certain customary purchase price adjustments) and 641,771 shares of the Company's common stock, par value $0.001 per share. This represents a reduction of approximately $50.0 million in total Transaction value to approximately $495.0 million based upon the closing value of the Company's common stock on June 27, 2025. The Company continues to anticipate that the Transaction will be completed in 2025. See Note 2, "Acquisitions," in the Notes to the Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for further information.

The U.S. government has implemented export regulations for U.S. semiconductor technology sold or provided to customers in China, which have limited our ability to provide certain products and services to customers in China, over the past several years. The U.S. government continues to issue new export licensing requirements, and additional updates and other

------

[**<u>**Table of Contents**</u>**](#toc_page)

requirements that have had the effect of further limiting our ability to provide certain products and services to customers outside the United States, including in China.

The recent imposition of tariffs by the U.S. government, and countermeasures taken by foreign countries, has had and will likely continue to have an adverse impact on our business in the near-term. The full extent of the impact is currently uncertain and will depend both on future developments in global trade policy and the extent to which our efforts to mitigate tariff impacts are successful. We are continuously assessing the impact of tariffs and related governmental actions on our business.

For a discussion of the risks related to our business and operations, see Part I, Item 1A – Risk Factors of the 2024 Form 10-K and Part II, Item 1A – Risk Factors of this Form 10-Q.

**Results of Operations for the Three and Nine Months Ended September 27, 2025 and September 28, 2024** 

*Revenue.* Our revenue is primarily derived from the sale of our systems, software licensing, services and spare parts. Our revenue of $218.2 million decreased 14% for the three months ended September 27, 2025 as compared to the three months ended September 28, 2024, for which revenue totaled $252.2 million. For the nine-months ended September 27, 2025 and September 28, 2024, our revenue totaled $738.4 million and $723.4 million, respectively, representing a year-over-year increase of 2%.

The following table lists, for the periods indicated, the different sources of our revenue in dollars and as percentages of our total revenue:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 27,** | **September 28,** | **September 28,** | **September 27,** | **September 27,** | **September 28,** | **September 28,** |
|  | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
|  | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** |
| Systems and software | $173795 | 80% | $217135 | 86% | $619451 | 84% | $622400 | 86% |
| Parts | 23930 | 11% | 19995 | 8% | 61955 | 8% | 56890 | 8% |
| Services | 20468 | 9% | 15080 | 6% | 56991 | 8% | 44092 | 6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $218193 | 100% | $252210 | 100% | $738397 | 100% | $723382 | 100% |

---

Total systems and software revenue decreased $43.3 million and $2.9 million for the three and nine months ended September 27, 2025, respectively, as compared to the three and nine months ended September 28, 2024. The decreases for the three and nine months ended September 27, 2025 were primarily attributable to lower sales to DRAM, foundry and power customers in the specialty device and advanced packaging market. These year over year decreases in systems and software revenue were partially offset by increased sales to OSAT customers in the specialty device and advanced packaging market and increased sales to foundry and DRAM customers in the advanced node market. The increase in total parts and services revenue for the three and nine months ended September 27, 2025, as compared to the three and nine months ended September 28, 2024, was primarily due to higher parts sales and service contract revenue.

*Gross Profit.* Our gross profit has been and will likely continue to be affected by a variety of factors, including manufacturing efficiencies, provision for excess and obsolete inventory, pricing by competitors or suppliers, new product introductions, production volume, customization and reconfiguration of systems, international and domestic sales mix, system and software product mix and parts and service margins.

The following table lists, for the periods indicated, our gross profit in dollars and as percentages of our total revenue:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** | **September 27,** | **September 28,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** |
| Gross profit | $110623 | $136379 | $375978 | $382900 |
| Gross profit as a percentage of revenue | 50.7% | 54.1% | 50.9% | 52.9% |

---

The decrease in gross profit as a percentage of revenue for the three and nine months ended September 27, 2025 as compared to the three and nine months ended September 28, 2024 was primarily due to restructuring and other expenses for the write down of excess and obsolete inventory.

------

[**<u>**Table of Contents**</u>**](#toc_page)

*Operating Expenses.* 

Our operating expenses consist of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*<u>Research and Development</u>.* We believe that it is critical to continue to make substantial investments in research and development to ensure the availability of innovative technology that meets the current and projected requirements of our customers' most advanced designs. We have maintained and intend to continue our commitment to investing in research and development in order to continue to offer new products and technologies. Accordingly, we devote a significant portion of our technical, management and financial resources to research and development programs. Research and development expenditures consist primarily of salaries and related expenses of employees engaged in research, design and development activities. These expenditures also include consulting fees, the cost of related supplies and legal costs to defend our patents. Our research and development expenses were $32.5 million and $95.8 million for the three and nine-month periods ended September 27, 2025, respectively, as compared to $28.3 million and $81.9 million for the three and nine-month periods ended September 28, 2024, respectively. The increase in research and development expenses of $4.2 million for the three-month period ended September 27, 2025, as compared to the three-month period ended September 28, 2024 was primarily due to increases in compensation costs and depreciation. The increase in research and development expenses of $13.9 million for the nine-month period ended September 27, 2025, as compared to the nine-month period ended September 28, 2024 was primarily due to increases in compensation costs, hardware and software project costs, production expenses, travel expenses, outside service costs and depreciation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*<u>Sales and Marketing</u>.* Sales and marketing expenses are primarily comprised of salaries, commissions and related costs for sales and marketing personnel, as well as other non-personnel related expenses. Our sales and marketing expenses were $17.1 million and $51.7 million for the three and nine-month periods ended September 27, 2025, respectively, compared to $19.5 million and $56.6 million for the three and nine-month periods ended September 28, 2024, respectively. The decrease in sales and marketing expenses of $2.4 million for the three-month period ended September 27, 2025, as compared to the three-month period ended September 28, 2024, was primarily due to decreases in compensation costs and production expenses. The decrease in sales and marketing expenses of $4.9 million for the nine-month period ended September 27, 2025, as compared to the nine-month period ended September 28, 2024, was primarily due to decreases in compensation costs and outside services and fees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*<u>General and Administrative</u>.* General and administrative expenses are primarily comprised of salaries and related costs for corporate and administrative personnel, as well as other non-personnel related expenses. Our general and administrative expenses were $24.8 million and $72.6 million for the three and nine-month periods ended September 27, 2025, respectively, as compared to $20.3 million and $57.4 million for the three and nine-month periods ended September 28, 2024, respectively. The increase in general and administrative expenses of $4.5 million for the three-month period ended September 27, 2025, as compared to the three-month period ended September 28, 2024, was primarily due to increases in compensation costs, outside service costs and depreciation. The increase in general and administrative expenses of $15.2 million for the nine-month period ended September 27, 2025, as compared to the nine-month period ended September 28, 2024, was primarily due to increases in compensation costs and outside service costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*<u>Amortization of Identifiable Intangible Assets</u>.* Amortization of identifiable intangible assets was $8.4 million and $25.3 million for the three and nine-month periods ended September 27, 2025, respectively, compared to $13.1 million and $39.3 million for the three and nine-month periods ended September 28, 2024, respectively. The decreases in amortization of identifiable intangible assets of $4.7 million and $14.0 million for the three and nine-month periods ended September 27, 2025, as compared to the three and nine-month periods ended September 28, 2024, was primarily due to certain assets becoming fully amortized.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*<u>Restructuring and Other</u>*<u>.</u> Restructuring and other expenses were $4.1 million and $11.4 million for the three and nine-month periods ended September 27, 2025, respectively, compared to $2.2 million and $3.0 million for the three and nine-month periods ended September 28, 2024, respectively. The increases in restructuring and other expenses of $1.9 million and $8.4 million for the three and nine-month periods ended September 27, 2025, as compared to the three and nine-month periods ended September 28, 2024, were primarily due to business transformation projects that includes the streamlining of various operating activities.

------

[**<u>**Table of Contents**</u>**](#toc_page)

*Interest income, net*. Net interest income was $9.3 million and $27.2 million for the three and nine-month periods ended September 27, 2025, respectively, as compared to $8.7 million and $24.5 million for the three and nine-month periods ended September 28, 2024, respectively. The increases in net interest income for the three and nine-month periods ended September 27, 2025, as compared to the three and nine-month periods ended September 28, 2024, were due to higher cash and marketable securities balances, partially offset by lower interest rates during the 2025 period.

*Other (expense) income, net*. Other expense, net was $1.0 million and $0.7 for the three-month period ended September 27, 2025 and the three-month period ended September 28, 2024, respectively. Other expense, net was $2.9 million for the nine-month period ended September 27, 2025, as compared to other income, net of $10 thousand for the nine-month period ended September 28, 2024. Foreign exchange losses during the 2025 period versus foreign exchange gains in the 2024 period were the primary drivers contributing to the period over period changes.

*Income Taxes*. We recorded an income tax provision of $3.8 million and $17.1 million for the three and nine-month periods ended September 27, 2025, respectively, as compared to $8.0 million and $16.3 million for the three and nine-month periods ended September 28, 2024, respectively. Our effective tax rate of 12% for both the three and nine-month periods ended September 27, 2025, differed from the statutory rate of 21%, primarily due to research and development tax credits and the deduction related to foreign derived intangible income ("FDII") for the three month period ended September 27, 2025. For the nine month period ended September 27, 2025, research and development tax credits, the deduction related to FDII and excess tax benefits associated with equity compensation contributed to the difference with the statutory rate. Our effective tax rate of 13% and 10% for the three and nine-month periods ended September 28, 2024, respectively, each differed from the statutory rate of 21%, primarily due to research and development tax credits, the deduction related to FDII, and excess tax benefits associated with equity compensation.

Our future effective income tax rate depends on various factors, such as possible changes in tax legislation, the geographic composition of our pre-tax income, the amount of our pre-tax income as business activities fluctuate, non-deductible expenses incurred in connection with business combinations, and research and development tax credits as a percentage of aggregate pre-tax income.

We currently have a partial valuation allowance recorded for certain foreign and state loss and credit carryforwards where the realizability of such deferred tax assets is substantially in doubt. Each quarter we assess the likelihood that we will be able to recover our deferred tax assets primarily relating to state research and development credits. We consider available evidence, both positive and negative, including historical levels of income, expectations and risks associated with estimates of future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for a valuation allowance. As a result of our analysis, we concluded that it is more likely than not that a portion of our net deferred tax assets will not be realized. Therefore, we continue to provide a valuation allowance against certain net deferred tax assets. We continue to monitor available evidence and may reverse some or all of the valuation allowance in future periods, if appropriate.

The Organization for Economic Co-operation and Development ("OECD") has been working on a Base Erosion and Profits Shifting project that, upon implementation, would change various aspects of the existing framework under which our tax obligations are determined in many of the countries in which we operate. In this regard, the OECD has proposed policies aiming to modernize global tax systems, including a country-by-country 15% minimum effective tax rate ("Pillar Two") for multinational companies. Numerous countries have enacted, or are in the process of enacting, legislation to implement the Pillar Two model rules with a subset of the rules becoming effective during the current year, and the remaining rules becoming effective in later periods. In June 2025, the Group of Seven ("G7") countries (Canada, France, Germany, Italy, Japan, the U.K. and the United States) agreed to exclude U.S. Multi-National entities (MNEs) from certain aspects of Pillar Two (the "G7 Statement") in exchange for the United States not imposing retaliatory taxes through the One Big Beautiful Bill Act. We will continue to monitor the G7 Statement, which has not yet been incorporated into the OECD framework. At this point in time, we do not expect any material tax impact associated with Pillar Two rules in the countries where we operate. As these rules continue to evolve with new legislation and guidance, we will continue to monitor and account for the enactment of Pillar Two and the potential impacts such rules may have on our effective tax rate and cash flows in future years.

On July 4, 2025, the United States enacted tax reform legislation through the One Big Beautiful Bill Act. Included in this legislation are provisions that allow for the immediate expensing of domestic U.S. research and development expenses, immediate expensing of certain capital expenditures, and other changes to the U.S. taxation of profits derived from foreign operations. The impact of the Act has been accounted for in the provision for taxes for the quarter ended September 27, 2025 and the amount is determined to be immaterial. The Company continues to evaluate the impact the new legislation will have on the Consolidated Financial Statements for future years. However, as the assessment is ongoing, the Company is not able to quantify the impact at this time.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Liquidity and Capital Resources**

Our cash, cash equivalents and marketable securities consist of the following in dollars for the periods indicated:

---

| | | |
|:---|:---|:---|
|  | **September 27,<br>2025** | **December 28, 2024** |
|  | **(in thousands)** | **(in thousands)** |
| Cash and cash equivalents | $603085 | $212945 |
| Marketable securities | 380843 | 639383 |
| &nbsp;&nbsp;Total cash, cash equivalents and marketable securities | $983928 | $852328 |

---

***Sources and Uses of Cash***

A summary of net cash and cash equivalents provided by (used in) operating, investing, and financing activities is as follows in dollars for the periods indicated:

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,** | **September 28,** |
|  | **2025** | **2024** |
|  | **(in thousands)** | **(in thousands)** |
| Net cash and cash equivalents provided by operating activities | $233319 | $189677 |
| Net cash and cash equivalents provided by (used in) investing activities | $231931 | $(222451) |
| Net cash and cash equivalents used in financing activities | $(77864) | $(10000) |

---

***Operating Activities***

Net cash and cash equivalents provided by operating activities for the nine months ended September 27, 2025 were $233.3 million. The net cash and cash equivalents provided by operating activities during the nine months ended September 27, 2025 resulted primarily from net income, adjusted to exclude the effect of non-cash operating charges, of $193.3 million. Significant non-cash operating charges included depreciation, amortization, share-based compensation, provision for inventory valuation and deferred income taxes. Cash provided by operating activities for the first nine months of fiscal 2025 increased compared to the corresponding period in fiscal 2024 primarily due to higher cash collections.

Our working capital was $1,382.1 million at September 27, 2025 and $1,307.4 million at December 28, 2024.

***Investing Activities***

Net cash and cash equivalents provided by investing activities for the nine months ended September 27, 2025 were $231.9 million. During the nine months ended September 27, 2025, net cash and cash equivalents provided by investing activities included proceeds from maturities and sales of marketable securities of $684.5 million, partially offset by purchases of marketable securities of $421.2 million, capital expenditures of $23.4 million and purchases of non-marketable equity securities of $8.0 million.

From time to time, we evaluate whether to acquire new or complementary businesses, products or technologies. We may fund all of or a portion of the price of these investments or acquisitions in cash, stock, or a combination of cash and stock. Our proposed acquisition of Semilab will cost $432.3 million in cash (subject to certain customary purchase price adjustments) and 641,771 shares of our common stock, par value $0.001 per share. See Note 2 of the Condensed Consolidated Financial Statements for further discussion regarding this proposed acquisition.

***Financing Activities***

Net cash and cash equivalents used in financing activities for the nine months ended September 27, 2025 were $77.9 million. During the nine months ended September 27, 2025, financing activities used cash primarily for purchases of common stock of $75.0 million and tax payments related to shares withheld to satisfy employee tax obligations in connection with the vesting of awards under share-based compensation plans of $12.6 million, partially offset by proceeds from sales of shares through share-based compensation plans of $9.7 million.

------

[**<u>**Table of Contents**</u>**](#toc_page)

In February 2024, our Board of Directors approved a share repurchase authorization, which allows the Company to repurchase up to $200 million worth of shares of its common stock. Repurchases may be made through both public market and private transactions from time to time. During the three and nine months ended September 27, 2025, we repurchased 0 and 492 thousand shares of common stock under this repurchase authorization, respectively. As of September 27, 2025, there was $99.9 million available for future share repurchases under this share repurchase authorization.

We have a credit agreement with a bank that provides for a variable-rate line of credit that is secured by the marketable securities we have with the bank. We are permitted to borrow up to 70% of the value of eligible securities held at the time the line of credit is accessed, up to a maximum of $100.0 million. As of September 27, 2025, the available line of credit was $100.0 million with an available interest rate of 4.8%. The credit agreement is available to us until such time that either party terminates the arrangement at its discretion. As of the date of this filing, we have not utilized the line of credit.

Our future capital requirements will depend on many factors, including the timing and amount of our revenue and our investment decisions, which will affect our ability to generate additional cash. We expect that our existing cash, cash equivalents, marketable securities and availability under our line of credit will be sufficient to meet our anticipated cash requirements for working capital, capital expenditures, and other cash needs for the next 12 months following the filing of this Form 10-Q. Thereafter, if cash generated from operations and financing activities is insufficient to satisfy our working capital requirements, we may seek additional funding through bank borrowings, sales of securities or other means. A reduction in or volatility with respect to our stock price or a general market downturn could materially impact our ability to sell securities on favorable terms or at all. There can be no assurance that we will be able to raise any such capital on terms acceptable to us or at all.

**Item 3. Quantitative and Qualitati** **ve Disclosures About Market Risk**

There have been no material changes in market risk from the information presented in Part II, Item 7A. "Quantitative and Qualitative Disclosures About Market Risk," in the 2024 Form 10-K.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in SEC rules and forms. These controls and procedures are also designed to ensure that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating disclosure controls and procedures, we have recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Management is required to apply judgment in evaluating its controls and procedures.

We performed an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to assess the effectiveness of the design and operation of our disclosure controls and procedures under the Exchange Act as of September 27, 2025. Based on that evaluation, our management, including our principal executive officer and principal financial officer, concluded that our disclosure controls and procedures were effective as of September 27, 2025 at the reasonable assurance level.

**Changes in Internal Control over Financial Reporting**

In the third quarter of 2025, we completed the installation and integration of a new enterprise resource planning system. The new system upgraded our overall information system capabilities, including our financial reporting systems, and supports improved business processes and enhanced internal controls. There have been no other changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during our fiscal quarter ended September 27, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**PART II OTHER** **INFORMATION**

**Item 1. Legal Proceedings**

For a description of our material pending legal proceedings refer to the information set forth under "Legal Matters" of Note 8, "Commitments and Contingencies," to the Condensed Consolidated Financial Statements included in Part 1, Item 1 of this Form 10-Q.

**Item 1A. Risk Factors.**

There have been no material changes from the risk factors previously disclosed under the heading "Risk Factors" in the 2024 Form 10-K, as updated by the risk factors previously disclosed under the heading "Risk Factors" in the Company's Quarterly Reports on Form 10-Q for the quarterly periods ended March 29, 2025, filed with the SEC on May 7, 2025, and June 28, 2025, filed with the SEC on August 7, 2025. We may disclose additional changes to risk factors or additional factors from time to time in our future filings with the SEC.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

In February 2024, the Onto Innovation Board of Directors approved a new share repurchase authorization, which allows the Company to repurchase up to $200 million worth of shares of its common stock. There were 0 and 492 thousand shares of common stock repurchased under this authorization during the three and nine months ended September 27, 2025, respectively. There was $99.9 million available for future share repurchases under this share repurchase authorization at September 27, 2025. For further information, see Note 16, "Share Repurchase Authorization," of the Notes to the Condensed Consolidated Financial Statements.

In addition to our share repurchase program, we withhold common stock shares associated with net share settlements to cover tax withholding obligations upon the vesting of restricted stock unit awards under the Company's equity incentive program. During the three and nine months ended September 27, 2025, we withheld 3 thousand and 89 thousand shares through net share settlements, respectively. For the three and nine months ended September 27, 2025, net share settlements cost $0.4 million and $12.7 million, respectively. Please refer to Note 10, "Share-Based Compensation," of the Notes to the Condensed Consolidated Financial Statements for further discussion regarding our equity incentive plan.

The following table provides details of common stock purchased during the three months ended September 27, 2025 (in thousands, except per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number <br>of Shares <br>Purchased** | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Program** | **Maximum Approximate Dollar Value of Shares that May Yet be Purchased Under the Program** |
|  | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** |
| June 29, 2025 to July 28, 2025 | 2 | $100.23 |  | $99935 |
| July 29, 2025 to August 28, 2025 |  | $97.87 |  | $99935 |
| August 29, 2025 to September 27, 2025 | 1 | $104.56 |  | $99935 |
| &nbsp;&nbsp;&nbsp;&nbsp;Three months ended September 27, 2025 | 3 | $101.34 |  |  |

---

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

None.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Item 5. Other Information** Rule 10b5-1 Plan *Elections*

During the fiscal quarter ended September 27, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as those terms are defined in Item 408 of Regulation S-K).

**Item 6. Exhibits**

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| [<u>3.1</u>](https://www.sec.gov/Archives/edgar/data/0000704532/000119312519275593/d823487dex32.htm) | [<u>Amended and Restated Certificate of Incorporation of Onto Innovation Inc., dated October 25, 2019, incorporated by reference to Exhibit 3.2 to the Company's Form 8-K filed with the SEC on October 28, 2019 (File No. 001-39110).</u>](https://www.sec.gov/Archives/edgar/data/0000704532/000119312519275593/d823487dex32.htm) |
| [<u>3.2</u>](https://www.sec.gov/Archives/edgar/data/0000704532/000156459020001927/onto-ex31_41.htm) | [<u>Amended and Restated Bylaws of Onto Innovation Inc., dated January 22, 2020, incorporated by reference to Exhibit 3.1 to the Company's Form 8-K filed with the SEC on January 27, 2020 (File No. 001-39110).</u>](https://www.sec.gov/Archives/edgar/data/0000704532/000156459020001927/onto-ex31_41.htm) |
| [<u>10.1+^</u>](https://www.sec.gov/Archives/edgar/data/704532/000095017025095287/onto-ex10_1.htm) | [<u>Separation Agreement between Onto Innovation Inc. and Mark Slicer, dated July 9, 2025, incorporated by reference to Exhibit 10.1 to the Company's Form 8-K/A filed with the SEC on July 11, 2025 (File No. 001-39110).</u>](https://www.sec.gov/Archives/edgar/data/704532/000095017025095287/onto-ex10_1.htm) |
| [<u>10.2^^</u>](https://www.sec.gov/Archives/edgar/data/704532/000119312525236464/onto-ex2_1.htm) | [<u>Amendment to Equity Purchase Agreement, dated as of October 9, 2025, by and among Onto Innovation Inc., Semilab USA LLC, Semilab International Zrt. and Semilab Zrt., incorporated by reference to Exhibit 2.1 to the Company's Form 8-K filed with the SEC on October 10, 2025 (File No. 001-39110).</u>](https://www.sec.gov/Archives/edgar/data/704532/000119312525236464/onto-ex2_1.htm) |
| [<u>31.1\*</u>](onto-ex31_1.htm) | [<u>Rule 13a-14(a) Certification of Chief Executive Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](onto-ex31_1.htm) |
| [<u>31.2\*</u>](onto-ex31_2.htm) | [<u>Rule 13a-14(a) Certification of Chief Financial Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](onto-ex31_2.htm) |
| [<u>32.1\*\*</u>](onto-ex32_1.htm) | [<u>Certification of the Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](onto-ex32_1.htm) |
| [<u>32.2\*\*</u>](onto-ex32_2.htm) | [<u>Certification of the Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](onto-ex32_2.htm) |
| 101.INS\* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents |
| 104\* | Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101) |

---

------

\* Filed herewith.

\*\* Furnished herewith.

+ Management contract, compensatory plan or arrangement.

^ Certain identified information has been excluded from this exhibit in accordance with Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential.

^^ Schedules omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **Onto Innovation Inc.** | **Onto Innovation Inc.** |
| Date: | November 6, 2025 | By: | /s/ Michael P. Plisinski |
|  |  | Michael P. Plisinski | Michael P. Plisinski |
|  |  | Chief Executive Officer | Chief Executive Officer |
| Date: | November 6, 2025 | By: | /s/ Brian K. Roberts |
|  |  | Brian K. Roberts | Brian K. Roberts |
|  |  | Chief Financial Officer and Principal Accounting Officer | Chief Financial Officer and Principal Accounting Officer |

---

------

## Exhibit 31.1

# Exhibit 31.1
**Rule 13a-14(a) Certification of Chief Executive Officer<br>Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Michael P. Plisinski, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Onto Innovation Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2025

---

| | |
|:---|:---|
| By: | /s/ Michael P. Plisinski |
|  | **Michael P. Plisinski** |
|  | **Chief Executive Officer** |

---

------

## Exhibit 31.2

# Exhibit 31.2
**Rule 13a-14(a) Certification of Chief Financial Officer<br>Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Brian K. Roberts, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Onto Innovation Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2025

---

| | |
|:---|:---|
| By: | /s/ Brian K. Roberts |
|  | **Brian K. Roberts** |
|  | **Chief Financial Officer** |

---

------

## Exhibit 32.1

# Exhibit 32.1
**CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Michael P. Plisinski, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Onto Innovation Inc. on Form 10-Q for the period ended September 27, 2025 fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Onto Innovation Inc.

Date: November 6, 2025

---

| | |
|:---|:---|
| By: | /s/ Michael P. Plisinski |
|  | **Michael P. Plisinski** |
|  | **Chief Executive Officer** |

---

------

## Exhibit 32.2

# Exhibit 32.2
**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Brian K. Roberts, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Onto Innovation Inc. on Form 10-Q for the period ended September 27, 2025 fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Onto Innovation Inc.

Date: November 6, 2025

---

| | |
|:---|:---|
| By: | /s/ Brian K. Roberts |
|  | **Brian K. Roberts** |
|  | **Chief Financial Officer** |

---

------